UK Markets close in 6 hrs 34 mins

Second Sight Medical Products, Inc. (EYES)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.9100+0.0900 (+2.36%)
At close: 4:00PM EDT
3.9900 +0.08 (2.05%)
Pre-market: 04:50AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.8200
Open3.8100
Bid0.0000 x 2200
Ask4.0000 x 1400
Day's range3.8000 - 4.0200
52-week range0.6910 - 20.0000
Volume1,509,725
Avg. volume6,189,371
Market cap109.125M
Beta (5Y monthly)3.40
PE ratio (TTM)N/A
EPS (TTM)-0.3920
Earnings date26 Jun 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Second Sight Medical Products Announces Closing of Public Offering

    LOS ANGELES, June 25, 2021--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $5.00 per share, which includes 1,500,000 shares sold upon full exercise of the underwrit

  • Business Wire

    Second Sight Medical Products Announces Pricing of Public Offering

    LOS ANGELES, June 23, 2021--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and o

  • Business Wire

    Second Sight Medical Products Announces Proposed Public Offering of Common Stock

    LOS ANGELES, Jun 22, 2021--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight" or the "Company") a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assur